Search research articles
Contact Us
Filters
Showing results (31-40 of 58) with videos related to
Page
of 6
Sort By:
Lupus
|
November 22, 2017
Association between false-positive TORCH and antiphospholipid antibodies in healthy pregnant women
S De Carolis, S Tabacco, F Rizzo, et al.
Lupus
|
May 29, 2012
The relationship between TORCH complex false positivity and obstetric outcome in patients with antiphospholipid syndrome
S De Carolis, S Santucci, A Botta, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1993
Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate
F Levi, B Perpoint, C Garufi, et al.
American Journal of Clinical Oncology
|
February 1, 1995
A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer
S Iacobelli, C Garufi, L Irtelli, et al.
Medical Oncology and Tumor Pharmacotherapy
|
January 1, 1991
5-Fluorouracil (FU) and mitomycin C (MMC) in the management of colorectal carcinoma. Part II. In vitro activity of the two drugs in short-term tumor cultures
F Franchi, C Barone, P Seminara, et al.
Oncology
|
January 1, 1990
Advanced colon cancer: staging and prognosis by CEA test
C Barone, A Astone, A Cassano, et al.
Autoimmunity Reviews
|
May 5, 2015
Is there any role for the hydroxychloroquine (HCQ) in refractory obstetrical antiphospholipid syndrome (APS) treatment?
S De Carolis, A Botta, S Salvi, et al.
European Journal of Cancer & Clinical Oncology
|
September 1, 1987
High-dose folinic acid (HDFA) combined with 5-fluorouracil (5-FU) in first line chemotherapy of advanced large bowel cancer
C Barone, A Astone, C Garufi, et al.
British Journal of Cancer
|
October 21, 2010
Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial
C Garufi, A Torsello, S Tumolo, et al.
Journal of Chemotherapy (Florence, Italy)
|
January 29, 2005
Role of P53 and Bcl-2 in advanced rectal carcinomas treated with adjuvant therapy
G Piperno, M Cosimelli, Donnorso R Perrone, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 58) with videos related to
Sort By:
Page
of 6
Lupus
|
November 22, 2017
Association between false-positive TORCH and antiphospholipid antibodies in healthy pregnant women
S De Carolis, S Tabacco, F Rizzo, et al.
Lupus
|
May 29, 2012
The relationship between TORCH complex false positivity and obstetric outcome in patients with antiphospholipid syndrome
S De Carolis, S Santucci, A Botta, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1993
Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate
F Levi, B Perpoint, C Garufi, et al.
American Journal of Clinical Oncology
|
February 1, 1995
A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer
S Iacobelli, C Garufi, L Irtelli, et al.
Medical Oncology and Tumor Pharmacotherapy
|
January 1, 1991
5-Fluorouracil (FU) and mitomycin C (MMC) in the management of colorectal carcinoma. Part II. In vitro activity of the two drugs in short-term tumor cultures
F Franchi, C Barone, P Seminara, et al.
Oncology
|
January 1, 1990
Advanced colon cancer: staging and prognosis by CEA test
C Barone, A Astone, A Cassano, et al.
Autoimmunity Reviews
|
May 5, 2015
Is there any role for the hydroxychloroquine (HCQ) in refractory obstetrical antiphospholipid syndrome (APS) treatment?
S De Carolis, A Botta, S Salvi, et al.
European Journal of Cancer & Clinical Oncology
|
September 1, 1987
High-dose folinic acid (HDFA) combined with 5-fluorouracil (5-FU) in first line chemotherapy of advanced large bowel cancer
C Barone, A Astone, C Garufi, et al.
British Journal of Cancer
|
October 21, 2010
Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial
C Garufi, A Torsello, S Tumolo, et al.
Journal of Chemotherapy (Florence, Italy)
|
January 29, 2005
Role of P53 and Bcl-2 in advanced rectal carcinomas treated with adjuvant therapy
G Piperno, M Cosimelli, Donnorso R Perrone, et al.
Page
of 6